If you have been wondering whether CRISPR Therapeutics at around $57 a share is a bargain or a bubble, you are not alone. This stock sits at the crossroads of high science and high expectations. The ...
A Mount Sinai team showed that the same leukemia mutation behaves differently depending on when it arises during development.
When you look at the big players in medical tech, Siemens Healthineers definitely stands out as a major competitor to GE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback